Tigecycline: Difference between revisions
Jump to navigation
Jump to search
imported>Howard C. Berkowitz (New page: '''Tigecycline''' is the first commercially available antibiotic of the glycylcycline class, which are a new family based on tetracyclines, but with molecular modifications to evad...) |
Pat Palmer (talk | contribs) (resolving ref syntax error) |
||
| (5 intermediate revisions by one other user not shown) | |||
| Line 1: | Line 1: | ||
{{subpages}} | |||
'''Tigecycline''' is the first commercially available antibiotic of the [[glycylcycline]] class, which are a new family based on [[tetracycline]]s, but with molecular modifications to evade some, but not all, tetracycline resistance mechanisms. <ref>{{citation | '''Tigecycline''' is the first commercially available antibiotic of the [[glycylcycline]] class, which are a new family based on [[tetracycline]]s, but with molecular modifications to evade some, but not all, tetracycline resistance mechanisms. <ref>{{citation | ||
| title = Tigecycline: what is it, and where should it be used? | | title = Tigecycline: what is it, and where should it be used? | ||
| Line 22: | Line 23: | ||
*Complicated Bacterial Peritonitis | *Complicated Bacterial Peritonitis | ||
*Complicated Skin and Skin Structure Infection | *Complicated Skin and Skin Structure Infection | ||
*Complicated Skin and Skin Structure [[E. | *Complicated Skin and Skin Structure ''[[E. coli]]'' Infection | ||
*Complicated Skin and Skin Structure ''[[Enterococcus faecalis]]'' Infection, | *Complicated Skin and Skin Structure ''[[Enterococcus faecalis]]'' Infection, | ||
{{col-break|width=33%}} | {{col-break|width=33%}} | ||
| Line 36: | Line 37: | ||
{{col-end}} | {{col-end}} | ||
==Mechanism of action== | ==Mechanism of action== | ||
The drug evades the Tet(A-E) efflux pumps<ref name=Petersen> Petersen PJ, Jacobus NV, Weiss WJ et al | The drug evades the Tet(A-E) efflux pumps<ref name=Petersen>{{citation | ||
| author = Petersen PJ, Jacobus NV, Weiss WJ et al | |||
| title = In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936) | |||
| journal = Antimicrob Agents Chemother | |||
| year = 1999 | volume = 43 | pages= 738–44 | |||
| url = http://jac.oxfordjournals.org/cgi/ijlink?linkType=ABST&journalCode=aac&resid=43/4/738}}</ref> which account for most acquired resistance to [[tetracycline]] and [[minocycline]] in ''[[Enterobacteriaceae]]'' and ''[[Acinetobacter|Acinetobacter spp.]]''; also the Tet(K) pumps, which occur widely in [[staphylococci]] conferring resistance to tetracycline though not [[minocycline]] or [[doxycycline]].<ref name=Chopra/> It binds to bacterial ribosomes that have been modified by the Tet(M) protein,<ref name=Petersen/> a mechanism that compromises all available tetracyclines, and which is frequent in Gram-positive cocci and ''[[Neisseriae]]'' spp.<ref>{{citation | |||
| author = Milatovic D, Schmitz FJ, Verhoef J ''et al.'' | |||
| title = Activities of the glycylcycline tigecycline (GAR-936) against 1,924 recent European clinical bacterial isolates. | |||
| journal = Antimicrob Agents Chemother | year = 2003 | volume = 47 | pages = 400–4 | |||
| url = http://jac.oxfordjournals.org/cgi/ijlink?linkType=ABST&journalCode=aac&resid=47/1/400}}</ref> | |||
==Administration== | |||
It is given intravenously, but should not be administered simultaneously, through common tubing, with [[amphotericin B]], [[chlorpromazine]], [[methylprednisolone]], or [[voriconazole]]. | |||
==References== | ==References== | ||
{{reflist|2}} | {{reflist|2}} | ||
Latest revision as of 13:30, 23 September 2024
Tigecycline is the first commercially available antibiotic of the glycylcycline class, which are a new family based on tetracyclines, but with molecular modifications to evade some, but not all, tetracycline resistance mechanisms. [1] Tetracycline resistance... [2]
Its labeled indications are:[3]
|
|
|
Mechanism of action
The drug evades the Tet(A-E) efflux pumps[4] which account for most acquired resistance to tetracycline and minocycline in Enterobacteriaceae and Acinetobacter spp.; also the Tet(K) pumps, which occur widely in staphylococci conferring resistance to tetracycline though not minocycline or doxycycline.[2] It binds to bacterial ribosomes that have been modified by the Tet(M) protein,[4] a mechanism that compromises all available tetracyclines, and which is frequent in Gram-positive cocci and Neisseriae spp.[5]
Administration
It is given intravenously, but should not be administered simultaneously, through common tubing, with amphotericin B, chlorpromazine, methylprednisolone, or voriconazole.
References
- ↑ David M. Livermore (2005), "Tigecycline: what is it, and where should it be used?", Journal of Antimicrobial Chemotherapy 56 (4): 611-614, DOI:10.1093/jac/dki291
- ↑ 2.0 2.1 Chopra I (1986), "Genetic and biochemical basis of tetracycline resistance", J Antimicrob Chemother 18 (Suppl C): 51–6
- ↑ Tigecycline IV, American Society of Health-System Pharmacists
- ↑ 4.0 4.1 Petersen PJ, Jacobus NV, Weiss WJ et al (1999), "In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936)", Antimicrob Agents Chemother 43: 738–44
- ↑ Milatovic D, Schmitz FJ, Verhoef J et al. (2003), "Activities of the glycylcycline tigecycline (GAR-936) against 1,924 recent European clinical bacterial isolates.", Antimicrob Agents Chemother 47: 400–4